Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00963508 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
A Phase 3 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
NCT00963508 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 403 participants.
The verdict
NCT00963508, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
Study Summary
In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.
Interventions
- DRUG Malathion gel 0.5%
- DRUG Permethrin 1% rinse (Nix Crème)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00963508
The ClinicalTrials.gov registry entry for NCT00963508 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 403 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Malathion gel 0.5% is the first listed.
NCT00963508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00963508 about?
NCT00963508 is a clinical study titled "Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice". In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years...
What is the current status of trial NCT00963508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2009-08. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00963508?
The interventions under investigation include: Malathion gel 0.5% (DRUG), Permethrin 1% rinse (Nix Crème) (DRUG).
Who is sponsoring clinical trial NCT00963508?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.